HIV Clinical Trial
Official title:
Study of the Attack Rate of COVID-19 Infection in Patients Infected With HIV and/or on Pre-exposure Prophylaxis (PrEP) and Possible Impact of Treatment With an HIV Protease Inhibitor
The SARS-CoV-2 epidemic was declared as a global pandemic by the WHO on March 12, 2020.
France is affected with approximately 120,000 biologically confirmed cases, as of April 30,
2020, a figure probably very underestimated. Its distribution in different populations, in
particular immunocompromised, has not yet been measured. The in vitro efficacy of lopinavir
coupled with ritonavir, an HIV protease inhibitor, on SARS-CoV, responsible for SARS has been
discussed and this therapeutic combination is currently being evaluated in patients infected
with COVID-19. The possible protective role of treatment with Lopinavir / ritonavir or
another HIV protease inhibitor has not been studied.
In addition, patients receiving HIV pre-exposure prophylaxis (PrEP) share certain
epidemiological and behavioral characteristics with HIV-infected patients.
The objective was to carry out an epidemiological study aimed at determining the attack rate
of COVID-19 infection in patients infected with HIV and or on PrEP and to analyze this attack
rate according to the characteristics of these 2 populations and in particular the existence
or not of an antiretroviral treatment comprising Lopinavir / Ritonavir or another inhibitor
of the HIV protease.
Cross-referencing of Virology Laboratory data (positive or negative screening) and
clinical-biological data can be easily carried out using a unique identification number in
the 2 software programs and will allow an almost exhaustive epidemiological analysis in 2
well identified populations.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
| Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
| Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
| Recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
| Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
| Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
| Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
| Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
| Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
| Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
| Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
| Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
| Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
| Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
| Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
| Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
| Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
| Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
| Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |